{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-24-000143","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.392723+00:00","generated_at":"2026-05-31T11:49:57.891877+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track","bullets":["Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.","Cash, equivalents & short-term investments $438.1M as of June 30, 2024.","Phase 2a PET imaging trial showed reduced total lung collagen and improved FVC in IPF patients on bexotegrast.","BEACON-IPF Phase 2b enrollment on track for Q1 2025 completion; data anticipated mid-2026.","Steve Krognes, former Denali Therapeutics CFO, appointed to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-24-000143","json":"https://secwatch.observer/filing/0001746473-24-000143.json","markdown":"https://secwatch.observer/filing/0001746473-24-000143.md","text":"https://secwatch.observer/filing/0001746473-24-000143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/0001746473-24-000143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000143/plrx-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:49:57.891877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}